Researchers used CRISPR and AI to identify two novel drug targets for psoriasis: the oxytocin receptor and ALOX5 enzyme. Topical gels containing these compounds reduced inflammation in mice as effectively as widely used injected therapies, offering a promising new approach to treating moderate-to-severe disease.
The Biohub initiative combines world-class compute capacity, frontier AI research and engineering, and state-of-the-art experimental and imaging technologies to accelerate science. The combined team will develop datasets, laboratory technologies, and modeling innovations needed to build next-generation AI systems for biological discovery.
CZI and NVIDIA collaborate to scale biological data processing, enabling next-generation virtual cell model development that unlocks insights about human biology. The new collaboration provides infrastructure and tools for researchers to apply AI to specific biological tasks.
The Chan Zuckerberg Initiative's latest AI model, GREmLN, is designed to predict and understand how genes interact within cells. It focuses on the molecular logic that defines gene behavior, allowing researchers to track critical changes pinpointing the earliest signs of disease.
The Center will develop personalized CRISPR on-demand treatments for children with severe inborn errors of immunity and metabolic disease. The initiative aims to make CRISPR cures more affordable and accessible, building on recent clinical success in treating ultra-rare genetic diseases.
Nine researchers receive unrestricted funding to pursue projects harnessing the immune system for early disease detection and prevention. The CZ Biohub NY Investigator Program supports research on novel immunotherapies, including precision cellular immunotherapy and advanced chemical probes.
The Chan Zuckerberg Initiative's CZ Biohub San Francisco and CZ Imaging Institute will join forces to develop novel imaging technologies that provide entirely new insights into human biology. This new Biohub aims to illuminate the dynamic architecture of living systems, making what was invisible visible, measurable and understandable.
Researchers have developed implantable sensors that track protein levels in real time, enabling continuous monitoring of inflammation at the cellular level. The technology has been successfully tested in diabetic rats, detecting changes in cytokine proteins associated with inflammation.
A collection of over 40 peer-reviewed papers marks a milestone toward understanding the human body and developing the first draft of the Human Cell Atlas. The research covers various tissues, cell types, and organs, introducing novel methods for analyzing complex single-cell and multi-omics datasets.
The Seattle Hub for Synthetic Biology will develop technologies to record the history of cells over time, revealing how changes in cells and genes influence human health and disease. This single-cell technology has the potential to revolutionize how scientists study cell biology.
The new Biohub in Chicago will focus on engineering technologies to study and measure human biology using embedded sensors. Scientists will aim to understand inflammation and develop treatments for diseases such as cancer, heart disease, and Alzheimer's.
The Chan Zuckerberg Initiative (CZI) has awarded $13 million in funding to 40 patient-led organizations working on rare disease research. These grants support the development of an international collaborative research network and strengthen organizational capacity.
The Chan Zuckerberg Initiative (CZI) has awarded nearly $28 million in grants to support the development of next-generation electron microscopy techniques for visualizing proteins in cells. The awards will enable researchers to obtain unprecedented views of protein structure, quantity, distribution, and interactions at near-atomic reso...
The Chan Zuckerberg Initiative (CZI) has awarded nearly $32 million in funding to support biomedical imaging researchers and technology development. The grants will focus on visualizing proteins in cells at near-atomic resolution to better understand health and disease.
The Chan Zuckerberg Initiative (CZI) has awarded $3 million in funding for open source software projects, including those essential to modern biomedicine. CZI also provided $1.7 million in funding to organizations advancing reproducibility practices and support for open research infrastructure.
The Chan Zuckerberg Initiative announces $4.5 million in funding for 30 pairs of researchers collaborating on novel approaches for gaining insight into neurodegenerative disorders like Alzheimer’s, Parkinson’s, and ALS. The grants support early- to mid-career scientists with the goal of increasing understanding of these diseases.
The California COVID Tracker will provide actionable viral genomic data to local public health jurisdictions, helping to inform policy decisions and reduce transmission. The program, launched in partnership with CZI and the CZ Biohub, aims to make SARS-CoV-2 tracing and analysis more efficient and accessible.
The Chan Zuckerberg Initiative provides $1.3 million in funding to NORD and EURORDIS, supporting organizational capacity building and Rare Disease Day awareness campaigns. The grants aim to unite and improve the lives of over 350 million people living with rare diseases worldwide.
The Chan Zuckerberg Initiative is awarding $3.8 million to support essential open source software projects in biomedical research and clinical medicine. These grants will enable awardees to improve software tools, enhance collaboration, and advance biomedical science.
The Chan Zuckerberg Initiative funds I AM ALS to create open source digital tools for building a movement against ALS and other rare diseases. This support aims to connect patients, caregivers, and scientists to accelerate progress in finding treatments and cures.
The Chan Zuckerberg Initiative has awarded $68 million to support the Human Cell Atlas, a collaborative effort between scientists from diverse disciplines. The funding will support networks of researchers who will map specific tissues in the healthy human body, generating cellular and molecular maps that will aid in understanding disease.
The Chan Zuckerberg Initiative's Rare As One Project aims to accelerate research and drive progress in the fight against rare diseases by providing funding, technology, and mentorship to patient-led organizations. The project will support up to $4.5 million in initial funding for capacity-building services and research networks.
The Centre of Genomics and Policy at McGill University will develop policies, tools, and support to enable efficient and ethical international data sharing for the Human Cell Atlas. The project aims to address regulatory and ethical questions arising from research at scale, including patient consent and guiding principles.
The Chan Zuckerberg Initiative is funding open-source software projects to improve image analysis and visualization in biomedicine. The projects will focus on developing and maintaining tools such as scikit-image, ImageJ, and CellProfiler to accelerate basic research and benefit the entire field.